High risk smoldering multiple myeloma (HR-SMM)

Clinical trials for High risk smoldering multiple myeloma (HR-SMM) explained in plain language.

Never miss a new study

Get alerted when new High risk smoldering multiple myeloma (HR-SMM) trials appear

Sign up with your email to follow new studies for High risk smoldering multiple myeloma (HR-SMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug linvoseltamab aims to stall multiple myeloma in High-Risk patients

Disease control Recruiting now

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

Matched conditions: HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM)

Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control

Last updated Aug 20, 2026 00:00 UTC

High risk smoldering multiple myeloma (HR-SMM)

Get alerted when new High risk smoldering multiple myeloma (HR-SMM) trials appear

New drug linvoseltamab aims to stall multiple myeloma in High-Risk patients